Stephen KL Chia
机构: Medical Oncology, British Columbia Cancer Agency
每年引用次数
引用次数
引用: 31,786
H-指数: 78
I10-指数 : 208
出版物: 538
Abstract A050: ARRY-380, an oral HER2 inhibitor: Final phase 1 results and conclusions
Virginia F. Borges , Steven K.L Chia , Susan D'Aloisio , Gina Fernetich
Molecular Cancer Research 11
2013
Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma
P H Watson , S K Chia , C C Wykoff , C Han
British Journal of Cancer 88 ( 7) 1065 -1070
111
2003
Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?
N LeVasseur , S K Chia
British Journal of Cancer 117 ( 2) 157 -300
1
2017
Efficacy of neratinib in hormone receptor-positive (HR+) patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer (BC): subgroup analyses from the phase III ExteNET trial
B. Ejlertsen , F.A. Holmes , S.K.L. Chia , H. Iwata
The Breast 44
2019
317P Updated results from the Canadian sub-population of the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial
N. Califaretti , C. Ferrario , E. Warner , A.A. Joy
Annals of Oncology 31
2020
329P Ribociclib (RIB) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and resistance to prior endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials
SA Hurvitz , SC Lee , G Jerusalem , SA Im
Annals of Oncology 31
2020
326P Exploratory analysis of TreatER+ight: A Canadian prospective real-world observational study in HR+ advanced breast cancer
C. Doyle , T.A. Vandenberg , C. Ferrario , N. Califaretti
Annals of Oncology 31
2020
309P Real-world effectiveness of alpelisib (ALP) + fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2–) PIK3CA-mutated (Mut) advanced breast cancer (ABC)
S. Turner , S.K.L. Chia , H. Kanakamedala , W-C. Hsu
Annals of Oncology 31
2020
352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC)
SA Hurvitz , SKL Chia , EM Ciruelos , X Hu
Annals of Oncology 31
2020
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
A. Prat , J.S. Parker , C. Fan , M.C.U. Cheang
Annals of Oncology 23 ( 11) 2866 -2873
162
2012
Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date.
S.K.L. Chia
Current Oncology 25 ( 11) 125 -130
9
2018
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.
S. Delaloge , D. Cella , Y. Ye , M. Buyse
Annals of Oncology 30 ( 4) 567 -574
9
2019
Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors
G. Batist , K. A. Gelmon , K. N. Chi , W. H. Miller
Clinical Cancer Research 15 ( 2) 692 -700
151
2009
Abstract PD3-12: PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial
SKL Chia , M Martin , FA Holmes , B Ejlertsen
Cancer Research 78
2018
Abstract S5-02: Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET)
A Chan , S Delaloge , FA Holmes , B Moy
Cancer Research 76
9
2016
Abstract P1-13-03: Effects of neratinib after trastuzumab-based adjuvant therapy in hormone receptor-positive HER2+ early-stage breast cancer: Exploratory analyses from the phase III ExteNET trial
SKL Chia , M Martin , H Iwata , B Moy
Cancer Research 78
2018
Carbonic anhydrase IX, a biomarker of hypoxia, as a poor prognostic factor in invasive breast cancer: results from 321 cases in a tissue microarray series.
SKL Chia , N Makretsov , M Cheang , E Yorida
BREAST CANCER RESEARCH AND TREATMENT 82 S120 -S120
2003
Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET)
A Chan , S Delaloge , FA Holmes , B Moy
CANCER RESEARCH 76
10
2016
PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial
SKL Chia , M Martin , FA Holmes , B Ejlertsen
San Antonio Breast Cancer Symposium (SABCS) 2018 PD3 -PD3
2018
Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
LL Siu , SJ Hotte , SA Laurie , S Singh
Journal of Clinical Oncology 29 ( 15_suppl) 5561 -5561
13
2011